Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 3,623 shares at $131.88 ($476K) on 2018-04-24, disclosed to the SEC on 2018-04-26.
Open-market sale of $476k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $129.58 | 241 | $31K | 6.6% |
| 2 | $130.62 | 300 | $39K | 8.2% |
| 3 | $131.88 | 500 | $66K | 13.9% |
| 4 | $133.09 | 500 | $67K | 14.0% |
| 5 | $128.72 | 300 | $39K | 8.1% |
| 6 | $129.45 | 100 |
| $13K |
| 2.7% |
| 7 | $130.94 | 600 | $79K | 16.5% |
| 8 | $132.05 | 541 | $71K | 15.0% |
| 9 | $132.05 | 541 | $71K | 15.0% |
| Total | $131.36 avg | 3,623 | $476K | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |